Recruiting

Observational Study

Sponsor:

Mayo Clinic

Code:

NCT07285863

Conditions

Exocrine Pancreatic Insufficiency

Chronic Pancreatitis

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Accepted

Interventions

Secretin (human synthetic) - ChiRhoClin

Study Details

Brief summary:

The purpose of this study is to collect pancreas fluid from the duodenum using the endoscopic pancreas function collection method in healthy participants after pancreatic stimulation with human secretin.

Conditions

Exocrine Pancreatic Insufficiency

Chronic Pancreatitis

Study ID

NCT07285863

Start date

Mar 11, 2026

Status verified date

Jul, 2026

Completion date

Mar, 2028

Anticipated

Primary completion date

Mar, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Accepted

Inclusion Criteria

  • Males or non-pregnant females
  • Age 18-80.
  • Participants must be in good health based on medical history (ASA Class 3 or below)
  • Participants must be willing and able to provide informed consent
  • Receiving an endoscopic ultrasound for a non-pancreatic indication

Exclusion Criteria

  • History of any form of pancreatitis and/or other pancreatic diseases (e.g. pancreatic cysts, pancreatic masses).
  • History of inflammatory bowel disease
  • History of vagotomy.
  • History of surgically altered upper gastrointestinal anatomy (e.g. gastric bypass, Billroth I/II)
  • History of liver disease
  • Pregnant women or nursing mothers
  • Regular use of anticholinergics
  • > 2 drinks of alcohol daily
  • Smokers (cigarette)

Study Design

Enrollment

24 participants

Anticipated

Intervention Model

Single group

Primary purpose

Other

Interventions and Outcome Measures

Arms

experimental: Healthy Participants

Healthy participants without pancreatic disease who are undergoing an endoscopic ultrasound for a non-pancreatic indication. Participants will be given a standard dose of intravenous human secretin (0.2 mcg/kg) during the endoscopic ultrasound. During this time, pancreatic fluid will be collected at 5 minutes, 10 minutes, 15 minutes, and 20 minutes after secretin administration.

Interventions

Secretin (human synthetic) - ChiRhoClin

During endoscopic ultrasound (EUS), a dose of intravenous secretin (0.2 µg/kg) will be administered over the course of 1 minute to stimulate pancreatic ductal cells to secrete pancreas fluid.

Duodenal fluid will be aspirated through the echoendoscope in 5 minute increments (5, 10, 15, and 20 minutes) after the secretin has been administered

Primary outcome measure

  • Pancreatic Fluid Bicarbonate Composition [ Time Frame: 5, 10, 15, and 20-minutes post-secretin administration ]
  • Pancreatic Fluid Sodium Composition [ Time Frame: 5, 10, 15, and 20-minutes post-secretin administration ]
  • Pancreatic Fluid Potassium Composition [ Time Frame: 5, 10, 15, and 20-minutes post-secretin administration ]
  • Pancreatic Fluid Chloride Composition [ Time Frame: 5, 10, 15, and 20-minutes post-secretin administration ]

Central Contacts and Locations

Central contacts

Liz Lemke

507-266-3317Lemke.Elizabeth@mayo.edu

Samuel Han, MD

han.samuel@mayo.edu

Locations

Mayo Clinic in Rochester

Recruiting

Rochester, Minnesota, United States, 55905

Contacts

Liz Lemke

507-266-3317

Principal Investigator:

Samuel Han, MD

More Information

Sponsor

Mayo Clinic

Last update posted

Jul 7, 2026

Last verified

Jul, 2026

Keywords

  • pancreatic function test
  • Pancreatic fluid composition

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Mayo Clinic on 2026-07-07.